| Fit-for-purpose method development and validation for successful biomarker measurement JW Lee, V Devanarayan, YC Barrett, R Weiner, J Allinson, S Fountain, ... Pharmaceutical research 23, 312-328, 2006 | 849 | 2006 |
| gdata: Various R programming tools for data manipulation GR Warnes, B Bolker, G Gorjanc, G Grothendieck, A Korosec, T Lumley, ... R package version 2 (3), 35, 2014 | 158 | 2014 |
| Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis JA Rogers, D Polhamus, WR Gillespie, K Ito, K Romero, R Qiu, ... Journal of pharmacokinetics and pharmacodynamics 39, 479-498, 2012 | 103 | 2012 |
| Activation of α7 acetylcholine receptors augments stimulation‐induced hippocampal theta oscillation CJ Siok, JA Rogers, B Kocsis, M Hajos European Journal of Neuroscience 23 (2), 570-574, 2006 | 85 | 2006 |
| The future is now: model‐based clinical trial design for Alzheimer's disease K Romero, K Ito, JA Rogers, D Polhamus, R Qiu, D Stephenson, R Mohs, ... Clinical Pharmacology & Therapeutics 97 (3), 210-214, 2015 | 79 | 2015 |
| A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in … JL Gross, J Rogers, D Polhamus, W Gillespie, C Friedrich, Y Gong, ... BMJ open 3 (3), e001844, 2013 | 50 | 2013 |
| Multiple comparisons of biodiversity JA Rogers, JC Hsu Biometrical Journal: Journal of Mathematical Methods in Biosciences 43 (5 …, 2001 | 33 | 2001 |
| Missing data in model‐based pharmacometric applications: points to consider MR Gastonguay, JL French, DF Heitjan, JA Rogers, JE Ahn, P Ravva The Journal of Clinical Pharmacology 50 (S9), 63S-74S, 2010 | 28 | 2010 |
| A confidence-set approach for finding tightly linked genomic regions S Lin, JA Rogers, JC Hsu The American Journal of Human Genetics 68 (5), 1219-1228, 2001 | 24 | 2001 |
| Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop K Romero, V Sinha, S Allerheiligen, M Danhof, J Pinheiro, N Kruhlak, ... Journal of pharmacokinetics and pharmacodynamics 41, 545-552, 2014 | 22 | 2014 |
| Population dose-response model for ADAS-cog scores in patients with Alzheimer’s disease by meta-analysis of a mixture of summary and individual data WR Gillespie, JA Rogers, K Ito, MR Gastonguay Clin Pharmacol Ther 85 (suppl 1), S62, 2009 | 10 | 2009 |
| An introduction to causal inference for pharmacometricians JA Rogers, H Maas, AP Pitarch CPT: Pharmacometrics & Systems Pharmacology 12 (1), 27-40, 2023 | 8 | 2023 |
| Population pharmacokinetics and exposure‐response of albinterferon alfa‐2b MM Riggs, TT Bergsma, JA Rogers, MR Gastonguay, GM Subramanian, ... The Journal of Clinical Pharmacology 52 (4), 475-486, 2012 | 8 | 2012 |
| Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency MA Tortorici, JA Rogers, O Vit, M Bexon, RA Sandhaus, J Burdon, ... British Journal of Clinical Pharmacology 83 (11), 2386-2397, 2017 | 7 | 2017 |
| Alzheimer's Disease Neuroimaging Initiative; Coalition Against Major Diseases. The future is now: model‐based clinical trial design for Alzheimer's disease K Romero, K Ito, JA Rogers, D Polhamus, R Qiu, D Stephenson, R Mohs, ... Clin Pharmacol Ther 97 (3), 210-214, 2015 | 6 | 2015 |
| Modeling and simulation of the exposure–response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD W Knebel, J Rogers, D Polhamus, J Ermer, MR Gastonguay Journal of pharmacokinetics and pharmacodynamics 42, 45-65, 2015 | 5 | 2015 |
| The value of evidence synthesis: Model-based meta-analysis based on the CAMD database, the ADNI AD cohort data, and literature meta-data J Rogers, D Polhamus, K Ito, K Romero, R Qiu, WR Gillespie, B Corrigan ASCPT Annual Meeting, 12-17, 2012 | 4 | 2012 |
| Micro-and Nanostructured Semiconductor Materials for Flexible and Stretchable Electronics JH Ahn, DH Kim, JA Rogers Comprehensive Semiconductor Science and Technology, 499-526, 2011 | 4 | 2011 |
| Causa Nostra: the potentially legitimate business of drawing causal inferences from observational data JA Rogers CPT: pharmacometrics & systems pharmacology 8 (5), 253, 2019 | 3 | 2019 |
| CLINICAL TRIAL SIMULATIONS IN ALZHEIMER'S DISEASE: EXAMPLE APPLICATIONS OF A MODELING AND SIMULATION TOOL IN DRUG DEVELOPMENT. R Qiu, J Rogers, D Polhamus, K Romero, K Ito, B Corrigan CLINICAL PHARMACOLOGY & THERAPEUTICS 91, S127-S128, 2012 | 3 | 2012 |
